Chemical Strategies towards the Development of Effective Anticancer Peptides


Cite item

Full Text

Abstract

Cancer is increasingly recognized as one of the primary causes of death and has become a multifaceted global health issue. Modern medical science has made significant advancements in the diagnosis and therapy of cancer over the past decade. The detrimental side effects, lack of efficacy, and multidrug resistance of conventional cancer therapies have created an urgent need for novel anticancer therapeutics or treatments with low cytotoxicity and drug resistance. The pharmaceutical groups have recognized the crucial role that peptide therapeutic agents can play in addressing unsatisfied healthcare demands and how these become great supplements or even preferable alternatives to biological therapies and small molecules. Anticancer peptides, as a vibrant therapeutic strategy against various cancer cells, have demonstrated incredible anticancer potential due to high specificity and selectivity, low toxicity, and the ability to target the surface of traditional "undruggable" proteins. This review will provide the research progression of anticancer peptides, mainly focusing on the discovery and modifications along with the optimization and application of these peptides in clinical practice.

About the authors

Cuicui Li

Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmacy, Cheeloo College of Medicine, Shandong University

Email: info@benthamscience.net

Kang Jin

Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, Shandong University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Luan, X.; Wu, Y.; Shen, Y.W.; Zhang, H.; Zhou, Y.D.; Chen, H.Z.; Nagle, D.G.; Zhang, W.D. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat. Prod. Rep., 2021, 38(1), 7-17. doi: 10.1039/D0NP00019A PMID: 32776055
  2. Xie, M.; Liu, D.; Yang, Y. Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification. Open Biol., 2020, 10(7), 200004. doi: 10.1098/rsob.200004 PMID: 32692959
  3. Felício, M.R.; Silva, O.N.; Gonçalves, S.; Santos, N.C.; Franco, O.L. Peptides with dual antimicrobial and anticancer activities. Front Chem., 2017, 5, 5. doi: 10.3389/fchem.2017.00005 PMID: 28271058
  4. Pan, X.; Xu, J.; Jia, X. Research progress evaluating the function and mechanism of anti-tumor peptides. Cancer Manag. Res., 2020, 12, 397-409. doi: 10.2147/CMAR.S232708 PMID: 32021452
  5. Muttenthaler, M.; King, G.F.; Adams, D.J.; Alewood, P.F. Trends in peptide drug discovery. Nat. Rev. Drug Discov., 2021, 20(4), 309-325. doi: 10.1038/s41573-020-00135-8 PMID: 33536635
  6. Mullard, A. 2021 FDA approvals. Nat. Rev. Drug Discov., 2022, 21(2), 83-88. doi: 10.1038/d41573-022-00001-9 PMID: 34983958
  7. Chai, T.T.; Ee, K.Y.; Kumar, D.T.; Manan, F.A.; Wong, F.C. Plant bioactive peptides: Current status and prospects towards use on human health. Protein Pept. Lett., 2021, 28(6), 623-642. doi: 10.2174/18755305MTEygMzc63 PMID: 33319654
  8. Li, X.; Guo, M.; Chi, J.; Ma, J. Bioactive peptides from walnut residue protein. Molecules, 2020, 25(6), 1285. doi: 10.3390/molecules25061285 PMID: 32178315
  9. Kaneko, K. Appetite regulation by plant-derived bioactive peptides for promoting health. Peptides, 2021, 144, 170608. doi: 10.1016/j.peptides.2021.170608 PMID: 34265369
  10. Chigumba, D.N.; Mydy, L.S.; de Waal, F.; Li, W.; Shafiq, K.; Wotring, J.W.; Mohamed, O.G.; Mladenovic, T.; Tripathi, A.; Sexton, J.Z.; Kautsar, S.; Medema, M.H.; Kersten, R.D. Discovery and biosynthesis of cyclic plant peptides via autocatalytic cyclases. Nat. Chem. Biol., 2022, 18(1), 18-28. doi: 10.1038/s41589-021-00892-6 PMID: 34811516
  11. Hitotsuyanagi, Y.; Ishikawa, H.; Hasuda, T.; Takeya, K. Isolation, structural elucidation, and synthesis of RA-XVII, a novel bicyclic hexapeptide from Rubia cordifolia, and the effect of side chain at residue 1 upon the conformation and cytotoxic activity. Tetrahedron Lett., 2004, 45(5), 935-938. doi: 10.1016/j.tetlet.2003.11.112
  12. Hitotsuyanagi, Y. Design and synthesis of analogues of RA-VII-an antitumor bicyclic hexapeptide from Rubiae radix. J. Nat. Med., 2021, 75(4), 752-761. doi: 10.1007/s11418-021-01542-w PMID: 34244894
  13. Aaghaz, S.; Gohel, V.; Kamal, A. Peptides as potential anticancer agents. Curr. Top. Med. Chem., 2019, 19(17), 1491-1511. doi: 10.2174/1568026619666190125161517 PMID: 30686254
  14. Han, B.; Goeger, D.; Maier, C.S.; Gerwick, W.H. The wewakpeptins, cyclic depsipeptides from a Papua new Guinea collection of the marine cyanobacterium Lyngbya semiplena. J. Org. Chem., 2005, 70(8), 3133-3139. doi: 10.1021/jo0478858 PMID: 15822975
  15. Luesch, H.; Moore, R.E.; Paul, V.J.; Mooberry, S.L.; Corbett, T.H. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod., 2001, 64(7), 907-910. doi: 10.1021/np010049y PMID: 11473421
  16. Pettit, G.R.; Kamano, Y.; Herald, C.L.; Tuinman, A.A.; Boettner, F.E.; Kizu, H.; Schmidt, J.M.; Baczynskyj, L.; Tomer, K.B.; Bontems, R.J. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc., 1987, 109(22), 6883-6885. doi: 10.1021/ja00256a070
  17. Yang, K.; Chen, B.; Gianolio, D.A.; Stefano, J.E.; Busch, M.; Manning, C.; Alving, K.; Gregory, R.C.; Brondyk, W.H.; Miller, R.J.; Dhal, P.K. Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation. Org. Biomol. Chem., 2019, 17(35), 8115-8124. doi: 10.1039/C9OB01639B PMID: 31460552
  18. Shnyder, S.; Cooper, P.; Millington, N.; Pettit, G.; Bibby, M. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int. J. Oncol., 2007, 31(2), 353-360. doi: 10.3892/ijo.31.2.353 PMID: 17611692
  19. Kaplon, H.; Muralidharan, M.; Schneider, Z.; Reichert, J.M. Antibodies to watch in 2020. MAbs, 2020, 12(1), 1703531. doi: 10.1080/19420862.2019.1703531 PMID: 31847708
  20. Tilly, H.; Morschhauser, F.; Sehn, L.H.; Friedberg, J.W.; Trněný, M.; Sharman, J.P.; Herbaux, C.; Burke, J.M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y.; Greil, R.; Mykhalska, L.; Bergua-Burgués, J.M.; Cheung, M.C.; Pinto, A.; Shin, H.J.; Hapgood, G.; Munhoz, E.; Abrisqueta, P.; Gau, J.P.; Hirata, J.; Jiang, Y.; Yan, M.; Lee, C.; Flowers, C.R.; Salles, G. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N. Engl. J. Med., 2022, 386(4), 351-363. doi: 10.1056/NEJMoa2115304 PMID: 34904799
  21. Canellos, G.P.; LaCasce, A.S. Brentuximab vedotin for stage III or IV hodgkin’s lymphoma. N. Engl. J. Med., 2018, 378(16), 1560. PMID: 29671468
  22. Hossain, M.B.; van der Helm, D.; Antel, J.; Sheldrick, G.M.; Sanduja, S.K.; Weinheimer, A.J. Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide. Proc. Natl. Acad. Sci., 1988, 85(12), 4118-4122. doi: 10.1073/pnas.85.12.4118 PMID: 3380783
  23. Potts, M.B.; McMillan, E.A.; Rosales, T.I.; Kim, H.S.; Ou, Y.H.; Toombs, J.E.; Brekken, R.A.; Minden, M.D.; MacMillan, J.B.; White, M.A. Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. Nat. Chem. Biol., 2015, 11(6), 401-408. doi: 10.1038/nchembio.1797 PMID: 25867045
  24. Maroun, J.A.; Belanger, K.; Seymour, L.; Matthews, S.; Roach, J.; Dionne, J.; Soulieres, D.; Stewart, D.; Goel, R.; Charpentier, D.; Goss, G.; Tomiak, E.; Yau, J.; Jimeno, J.; Chiritescu, G. Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann. Oncol., 2006, 17(9), 1371-1378. doi: 10.1093/annonc/mdl165 PMID: 16966366
  25. Jimenez, P.C.; Wilke, D.V.; Branco, P.C.; Bauermeister, A.; Rezende-Teixeira, P.; Gaudêncio, S.P.; Costa-Lotufo, L.V. Enriching cancer pharmacology with drugs of marine origin. Br. J. Pharmacol., 2020, 177(1), 3-27. doi: 10.1111/bph.14876 PMID: 31621891
  26. White, K.M.; Rosales, R.; Yildiz, S.; Kehrer, T.; Miorin, L.; Moreno, E.; Jangra, S.; Uccellini, M.B.; Rathnasinghe, R.; Coughlan, L.; Martinez-Romero, C.; Batra, J.; Rojc, A.; Bouhaddou, M.; Fabius, J.M.; Obernier, K.; Dejosez, M.; Guillén, M.J.; Losada, A.; Avilés, P.; Schotsaert, M.; Zwaka, T.; Vignuzzi, M.; Shokat, K.M.; Krogan, N.J.; García-Sastre, A. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 2021, 371(6532), 926-931. doi: 10.1126/science.abf4058 PMID: 33495306
  27. Scala, S. Molecular pathways: Targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment. Clin. Cancer Res., 2015, 21(19), 4278-4285. doi: 10.1158/1078-0432.CCR-14-0914 PMID: 26199389
  28. Pernas, S.; Martin, M.; Kaufman, P.A.; Gil-Martin, M.; Gomez Pardo, P.; Lopez-Tarruella, S.; Manso, L.; Ciruelos, E.; Perez-Fidalgo, J.A.; Hernando, C.; Ademuyiwa, F.O.; Weilbaecher, K.; Mayer, I.; Pluard, T.J.; Martinez Garcia, M.; Vahdat, L.; Perez-Garcia, J.; Wach, A.; Barker, D.; Fung, S.; Romagnoli, B.; Cortes, J. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: A phase 1, single-arm, dose-escalation trial. Lancet Oncol., 2018, 19(6), 812-824. doi: 10.1016/S1470-2045(18)30147-5 PMID: 29706375
  29. Kim, M.; Kang, N.; Ko, S.; Park, J.; Park, E.; Shin, D.; Kim, S.; Lee, S.; Lee, J.; Lee, S.; Ha, E.; Jeon, S.; Park, Y. Antibacterial and antibiofilm activity and mode of action of Magainin 2 against drug-resistant acinetobacter baumannii. Int. J. Mol. Sci., 2018, 19(10), 3041. doi: 10.3390/ijms19103041 PMID: 30301180
  30. Anand, P.; Grigoryan, A.; Bhuiyan, M.H.; Ueberheide, B.; Russell, V.; Quinoñez, J.; Moy, P.; Chait, B.T.; Poget, S.F.; Holford, M. Sample limited characterization of a novel disulfide-rich venom peptide toxin from terebrid marine snail Terebra variegata. PLoS One, 2014, 9(4), e94122. doi: 10.1371/journal.pone.0094122 PMID: 24713808
  31. Fahy, R.J.; Wewers, M.D. Pulmonary defense and the human cathelicidin hCAP-18/LL-37. Immunol. Res., 2005, 31(2), 075-090. doi: 10.1385/IR:31:2:075 PMID: 15778507
  32. Gaspar, D.; Freire, J.M.; Pacheco, T.R.; Barata, J.T.; Castanho, M.A.R.B. Apoptotic human neutrophil peptide-1 anti-tumor activity revealed by cellular biomechanics. Biochim. Biophys. Acta Mol. Cell Res., 2015, 1853(2), 308-316. doi: 10.1016/j.bbamcr.2014.11.006 PMID: 25447543
  33. Li, B.; Lyu, P.; Xi, X.; Ge, L.; Mahadevappa, R.; Shaw, C.; Kwok, H.F. Triggering of cancer cell cycle arrest by a novel scorpion venom-derived peptide-Gonearrestide. J. Cell. Mol. Med., 2018, 22(9), 4460-4473. doi: 10.1111/jcmm.13745 PMID: 29993185
  34. Cassoli, J.S.; Verano-Braga, T.; Oliveira, J.S.; Montandon, G.G.; Cologna, C.T.; Peigneur, S.; Pimenta, A.M.C.; Kjeldsen, F.; Roepstorff, P.; Tytgat, J.; de Lima, M.E. The proteomic profile of Stichodactyla duerdeni secretion reveals the presence of a novel O-linked glycopeptide. J. Proteomics, 2013, 87, 89-102. doi: 10.1016/j.jprot.2013.05.022 PMID: 23727489
  35. Pazgier, M.; Liu, M.; Zou, G.; Yuan, W.; Li, C.; Li, C.; Li, J.; Monbo, J.; Zella, D.; Tarasov, S.G.; Lu, W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl. Acad. Sci., 2009, 106(12), 4665-4670. doi: 10.1073/pnas.0900947106 PMID: 19255450
  36. Kang, J.; Zhao, G.; Lin, T.; Tang, S.; Xu, G.; Hu, S.; Bi, Q.; Guo, C.; Sun, L.; Han, S.; Xu, Q.; Nie, Y.; Wang, B.; Liang, S.; Ding, J.; Wu, K. A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cells. Cancer Lett., 2013, 339(2), 247-259. doi: 10.1016/j.canlet.2013.06.016 PMID: 23792224
  37. Liu, M.; Li, C.; Pazgier, M.; Li, C.; Mao, Y.; Lv, Y.; Gu, B.; Wei, G.; Yuan, W.; Zhan, C.; Lu, W.Y.; Lu, W. D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc. Natl. Acad. Sci., 2010, 107(32), 14321-14326. doi: 10.1073/pnas.1008930107 PMID: 20660730
  38. Zhan, C.; Zhao, L.; Wei, X.; Wu, X.; Chen, X.; Yuan, W.; Lu, W.Y.; Pazgier, M.; Lu, W. An ultrahigh affinity d-peptide antagonist Of MDM2. J. Med. Chem., 2012, 55(13), 6237-6241. doi: 10.1021/jm3005465 PMID: 22694121
  39. Kim, J.H.; Seok, J.K.; Kim, Y.M.; Boo, Y.C. Identification of small peptides and glycinamide that inhibit melanin synthesis using a positional scanning synthetic peptide combinatorial library. Br. J. Dermatol., 2019, 181(1), 128-137. doi: 10.1111/bjd.17634 PMID: 30637717
  40. Yin, Y.; Ochi, N.; Craven, T.W.; Baker, D.; Takigawa, N.; Suga, H. De novo carborane-containing macrocyclic peptides targeting human epidermal growth factor receptor. J. Am. Chem. Soc., 2019, 141(49), 19193-19197. doi: 10.1021/jacs.9b09106 PMID: 31752491
  41. Takada, Y.; Itoh, H.; Paudel, A.; Panthee, S.; Hamamoto, H.; Sekimizu, K.; Inoue, M. Discovery of gramicidin A analogues with altered activities by multidimensional screening of a one-bead-one-compound library. Nat. Commun., 2020, 11(1), 4935. doi: 10.1038/s41467-020-18711-2 PMID: 33004797
  42. Guardiola, S.; Díaz-Lobo, M.; Seco, J.; García, J.; Nevola, L.; Giralt, E. Peptides targeting EGF block the EGF-EGFR interaction. ChemBioChem, 2016, 17(8), 702-711. doi: 10.1002/cbic.201500525 PMID: 26677067
  43. Cha, N.; Han, X.; Jia, B.; Liu, Y.; Wang, X.; Gao, Y.; Ren, J. Structure-based design of peptides against HER2 with cytotoxicity on colon cancer. Artif. Cells Nanomed. Biotechnol., 2017, 45(3), 649-654. doi: 10.3109/21691401.2016.1167705 PMID: 27068253
  44. Chatterjee, S.; Lesniak, W.G.; Miller, M.S.; Lisok, A.; Sikorska, E.; Wharram, B.; Kumar, D.; Gabrielson, M.; Pomper, M.G.; Gabelli, S.B.; Nimmagadda, S. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochem. Biophys. Res. Commun., 2017, 483(1), 258-263. doi: 10.1016/j.bbrc.2016.12.156 PMID: 28025143
  45. Gabernet, G.; Gautschi, D.; Müller, A.T.; Neuhaus, C.S.; Armbrecht, L.; Dittrich, P.S.; Hiss, J.A.; Schneider, G. In silico design and optimization of selective membranolytic anticancer peptides. Sci. Rep., 2019, 9(1), 11282. doi: 10.1038/s41598-019-47568-9 PMID: 31375699
  46. Tada, N.; Horibe, T.; Haramoto, M.; Ohara, K.; Kohno, M.; Kawakami, K. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochem. Biophys. Res. Commun., 2011, 407(2), 383-388. doi: 10.1016/j.bbrc.2011.03.030 PMID: 21396910
  47. Zhang, P.; Ma, J.; Yan, Y.; Chen, B.; Liu, B.; Jian, C.; Zhu, B.; Liang, S.; Zeng, Y.; Liu, Z. Arginine modification of lycosin-I to improve inhibitory activity against cancer cells. Org. Biomol. Chem., 2017, 15(44), 9379-9388. doi: 10.1039/C7OB02233F PMID: 29090725
  48. Ke, M.; Dong, J.; Wang, Y.; Zhang, J.; Zhang, M.; Wu, Z.; Lv, Y.; Wu, R. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells. Int. J. Biochem. Cell Biol., 2018, 101, 39-48. doi: 10.1016/j.biocel.2018.05.013 PMID: 29800725
  49. Li, Y.; Lei, Y.; Wagner, E.; Xie, C.; Lu, W.; Zhu, J.; Shen, J.; Wang, J.; Liu, M. Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells. Bioconjug. Chem., 2013, 24(1), 133-143. doi: 10.1021/bc300537z PMID: 23241015
  50. Li, X.; Liu, C.; Chen, S.; Hu, H.; Su, J.; Zou, Y. d -Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions. Bioorg. Med. Chem. Lett., 2017, 27(20), 4678-4681. doi: 10.1016/j.bmcl.2017.09.014 PMID: 28916339
  51. Kluskens, L.D.; Nelemans, S.A.; Rink, R.; de Vries, L.; Meter-Arkema, A.; Wang, Y.; Walther, T.; Kuipers, A.; Moll, G.N.; Haas, M. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J. Pharmacol. Exp. Ther., 2009, 328(3), 849-854. doi: 10.1124/jpet.108.146431 PMID: 19038778
  52. Leshchiner, E.S.; Parkhitko, A.; Bird, G.H.; Luccarelli, J.; Bellairs, J.A.; Escudero, S.; Opoku-Nsiah, K.; Godes, M.; Perrimon, N.; Walensky, L.D. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc. Natl. Acad. Sci., 2015, 112(6), 1761-1766. doi: 10.1073/pnas.1413185112 PMID: 25624485
  53. Li, C.; Zhao, N.; An, L.; Dai, Z.; Chen, X.; Yang, F.; You, Q.; Di, B.; Hu, C.; Xu, L. Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C. Acta Pharm. Sin. B, 2021, 11(9), 2670-2684. doi: 10.1016/j.apsb.2021.06.013 PMID: 34589388
  54. Lin, T.; Min, H.; Jiang, C.; Niu, M.; Yan, F.; Xu, L.; Di, B. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors. Bioorg. Med. Chem., 2018, 26(12), 3429-3437. doi: 10.1016/j.bmc.2018.05.014 PMID: 29807699
  55. Deng, X.; Qiu, Q.; Wang, X.; Huang, W.; Qian, H. Design, synthesis, and biological evaluation of novel cholesteryl peptides with anticancer and multidrug resistance-reversing activities. Chem. Biol. Drug Des., 2016, 87(3), 374-381. doi: 10.1111/cbdd.12667 PMID: 26390861
  56. Li, S.; Zou, R.; Tu, Y.; Wu, J.; Landry, M.P. Cholesterol-directed nanoparticle assemblies based on single amino acid peptide mutations activate cellular uptake and decrease tumor volume. Chem. Sci., 2017, 8(11), 7552-7559. doi: 10.1039/C7SC02616A PMID: 29163910
  57. Wu, M.; Ai, S.; Chen, Q.; Chen, X.; Li, H.; Li, Y.; Zhao, X. Effects of glycosylation and d-amino acid substitution on the antitumor and antibacterial activities of bee venom peptide HYL. Bioconjug. Chem., 2020, 31(10), 2293-2302. doi: 10.1021/acs.bioconjchem.0c00355 PMID: 32786366
  58. Brinckerhoff, L.H.; Kalashnikov, V.V.; Thompson, L.W.; Yamshchikov, G.V.; Pierce, R.A.; Galavotti, H.S.; Engelhard, V.H.; Slingluff, C.L., Jr Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines. Int. J. Cancer, 1999, 83(3), 326-334. doi: 10.1002/(SICI)1097-0215(19991029)83:33.0.CO;2-X PMID: 10495424
  59. Jian, C.; Zhang, P.; Ma, J.; Jian, S.; Zhang, Q.; Liu, B.; Liang, S.; Liu, M.; Zeng, Y.; Liu, Z. The roles of fatty-acid modification in the activity of the anticancer peptide R-Lycosin-I. Mol. Pharm., 2018, 15(10), 4612-4620. doi: 10.1021/acs.molpharmaceut.8b00605 PMID: 30183307
  60. Sinthuvanich, C.; Veiga, A.S.; Gupta, K.; Gaspar, D.; Blumenthal, R.; Schneider, J.P. Anticancer β-hairpin peptides: Membrane-induced folding triggers activity. J. Am. Chem. Soc., 2012, 134(14), 6210-6217. doi: 10.1021/ja210569f PMID: 22413859
  61. Hao, X.; Yan, Q.; Zhao, J.; Wang, W.; Huang, Y.; Chen, Y. TAT modification of alpha-helical anticancer peptides to improve specificity and efficacy. PLoS One, 2015, 10(9), e0138911. doi: 10.1371/journal.pone.0138911 PMID: 26405806
  62. Coiffier, B.; Pro, B.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Borchmann, P.; Morschhauser, F.; Wilhelm, M.; Pinter-Brown, L.; Padmanabhan, S.; Shustov, A.; Nichols, J.; Carroll, S.; Balser, J.; Balser, B.; Horwitz, S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T- cell lymphoma after prior systemic therapy. J. Clin. Oncol., 2012, 30(6), 631-636. doi: 10.1200/JCO.2011.37.4223 PMID: 22271479
  63. Lopez, J.A.V.; Al-Lihaibi, S.S.; Alarif, W.M.; Abdel-Lateff, A.; Nogata, Y.; Washio, K.; Morikawa, M.; Okino, T. Wewakazole B, a cytotoxic cyanobactin from the Cyanobacterium Moorea producens collected in the red sea. J. Nat. Prod., 2016, 79(4), 1213-1218. doi: 10.1021/acs.jnatprod.6b00051 PMID: 26980238
  64. Kuroda, K.; Fukuda, T.; Krstic-Demonacos, M.; Demonacos, C.; Okumura, K.; Isogai, H.; Hayashi, M.; Saito, K.; Isogai, E. miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway. BMC Cancer, 2017, 17(1), 33. doi: 10.1186/s12885-016-3003-9 PMID: 28061765
  65. Niemirowicz, K.; Prokop, I.; Wilczewska, A.; Wnorowska, U.; Piktel, E.; Wątek, M.; Savage, P.; Bucki, R. Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells. Int. J. Nanomedicine, 2015, 10, 3843-3853. doi: 10.2147/IJN.S76104 PMID: 26082634
  66. Kaas, Q.; Craik, D. Bioinformatics-aided venomics. Toxins, 2015, 7(6), 2159-2187. doi: 10.3390/toxins7062159 PMID: 26110505
  67. Andreev, Y.A.; Kozlov, S.A.; Koshelev, S.G.; Ivanova, E.A.; Monastyrnaya, M.M.; Kozlovskaya, E.P.; Grishin, E.V. Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1). J. Biol. Chem., 2008, 283(35), 23914-23921. doi: 10.1074/jbc.M800776200 PMID: 18579526
  68. Madio, B.; Peigneur, S.; Chin, Y.K.Y.; Hamilton, B.R.; Henriques, S.T.; Smith, J.J.; Cristofori-Armstrong, B.; Dekan, Z.; Boughton, B.A.; Alewood, P.F.; Tytgat, J.; King, G.F.; Undheim, E.A.B. PHAB toxins: A unique family of predatory sea anemone toxins evolving via intra-gene concerted evolution defines a new peptide fold. Cell. Mol. Life Sci., 2018, 75(24), 4511-4524. doi: 10.1007/s00018-018-2897-6 PMID: 30109357
  69. Himaya, S.W.A.; Jin, A.H.; Dutertre, S.; Giacomotto, J.; Mohialdeen, H.; Vetter, I.; Alewood, P.F.; Lewis, R.J. Comparative venomics reveals the complex prey capture strategy of the piscivorous cone snail conus catus. J. Proteome Res., 2015, 14(10), 4372-4381. doi: 10.1021/acs.jproteome.5b00630 PMID: 26322961
  70. Campos, P.F.; Andrade-Silva, D.; Zelanis, A.; Paes Leme, A.F.; Rocha, M.M.T.; Menezes, M.C.; Serrano, S.M.T.; Junqueira-de-Azevedo, I.L.M. Trends in the evolution of snake toxins underscored by an integrative omics approach to profile the venom of the colubrid phalotris mertensi. Genome Biol. Evol., 2016, 8(8), 2266-2287. doi: 10.1093/gbe/evw149 PMID: 27412610
  71. Madio, B.; Undheim, E.A.B.; King, G.F. Revisiting venom of the sea anemone Stichodactyla haddoni: Omics techniques reveal the complete toxin arsenal of a well-studied sea anemone genus. J. Proteomics, 2017, 166, 83-92. doi: 10.1016/j.jprot.2017.07.007 PMID: 28739511
  72. Huang, Y.; Wiedmann, M.M.; Suga, H. RNA display methods for the discovery of bioactive macrocycles. Chem. Rev., 2019, 119(17), 10360-10391. doi: 10.1021/acs.chemrev.8b00430 PMID: 30395448
  73. Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, 1985, 228(4705), 1315-1317. doi: 10.1126/science.4001944 PMID: 4001944
  74. Rahbarnia, L.; Farajnia, S.; Babaei, H.; Majidi, J.; Veisi, K.; Ahmadzadeh, V.; Akbari, B. Evolution of phage display technology: From discovery to application. J. Drug Target., 2017, 25(3), 216-224. doi: 10.1080/1061186X.2016.1258570 PMID: 27819143
  75. Saw, P.E.; Song, E.W. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell, 2019, 10(11), 787-807. doi: 10.1007/s13238-019-0639-7 PMID: 31140150
  76. Hamzeh-Mivehroud, M.; Alizadeh, A.A.; Morris, M.B.; Bret Church, W.; Dastmalchi, S. Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov. Today, 2013, 18(23-24), 1144-1157. doi: 10.1016/j.drudis.2013.09.001 PMID: 24051398
  77. Omidfar, K.; Daneshpour, M. Advances in phage display technology for drug discovery. Expert Opin. Drug Discov., 2015, 10(6), 651-669. doi: 10.1517/17460441.2015.1037738 PMID: 25910798
  78. Heinis, C.; Winter, G. Encoded libraries of chemically modified peptides. Curr. Opin. Chem. Biol., 2015, 26, 89-98. doi: 10.1016/j.cbpa.2015.02.008 PMID: 25768886
  79. Schumacher, T.N.M.; Mayr, L.M.; Minor, D.L., Jr; Milhollen, M.A.; Burgess, M.W.; Kim, P.S. Identification of D-peptide ligands through mirror-image phage display. Science, 1996, 271(5257), 1854-1857. doi: 10.1126/science.271.5257.1854 PMID: 8596952
  80. Roberts, R.W.; Szostak, J.W. RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci., 1997, 94(23), 12297-12302. doi: 10.1073/pnas.94.23.12297 PMID: 9356443
  81. Goto, Y.; Katoh, T.; Suga, H. Flexizymes for genetic code reprogramming. Nat. Protoc., 2011, 6(6), 779-790. doi: 10.1038/nprot.2011.331 PMID: 21637198
  82. Murakami, H.; Ohta, A.; Ashigai, H.; Suga, H. A highly flexible tRNA acylation method for non-natural polypeptide synthesis. Nat. Methods, 2006, 3(5), 357-359. doi: 10.1038/nmeth877 PMID: 16628205
  83. Nawatha, M.; Rogers, J.M.; Bonn, S.M.; Livneh, I.; Lemma, B.; Mali, S.M.; Vamisetti, G.B.; Sun, H.; Bercovich, B.; Huang, Y.; Ciechanover, A.; Fushman, D.; Suga, H.; Brik, A. De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains. Nat. Chem., 2019, 11(7), 644-652. doi: 10.1038/s41557-019-0278-x PMID: 31182821
  84. Lam, K.S.; Salmon, S.E.; Hersh, E.M.; Hruby, V.J.; Kazmierski, W.M.; Knapp, R.J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature, 1991, 354(6348), 82-84. doi: 10.1038/354082a0 PMID: 1944576
  85. Elashal, H.E.; Cohen, R.D.; Elashal, H.E.; Raj, M. Oxazolidinone-mediated sequence determination of one-bead one-compound cyclic peptide libraries. Org. Lett., 2018, 20(8), 2374-2377. doi: 10.1021/acs.orglett.8b00717 PMID: 29617143
  86. Yang, P.P.; Li, Y.J.; Cao, Y.; Zhang, L.; Wang, J.Q.; Lai, Z.; Zhang, K.; Shorty, D.; Xiao, W.; Cao, H.; Wang, L.; Wang, H.; Liu, R.; Lam, K.S. Rapid discovery of self- assembling peptides with one-bead one-compound peptide library. Nat. Commun., 2021, 12(1), 4494. doi: 10.1038/s41467-021-24597-5 PMID: 34301935
  87. Singh, Y.; Rodriguez Benavente, M.C.; Al-Huniti, M.H.; Beckwith, D.; Ayyalasomayajula, R.; Patino, E.; Miranda, W.S.; Wade, A.; Cudic, M. Positional scanning MUC1 glycopeptide library reveals the importance of PDTR epitope glycosylation for lectin binding. J. Org. Chem., 2020, 85(3), 1434-1445. doi: 10.1021/acs.joc.9b02396 PMID: 31799848
  88. Pinilla, C.; Appel, J.R.; Borràs, E.; Houghten, R.A. Advances in the use of synthetic combinatorial chemistry: Mixture-based libraries. Nat. Med., 2003, 9(1), 118-122. doi: 10.1038/nm0103-118 PMID: 12514724
  89. Sun, Z.G.; Zhou, X.J.; Zhu, M.L.; Ding, W.Z.; Li, Z.; Zhu, H.L. Synthesis and biological evaluation of novel aryl-2H-pyrazole derivatives as potent non-purine xanthine oxidase inhibitors. Chem. Pharm. Bull., 2015, 63(8), 603-607. doi: 10.1248/cpb.c15-00282 PMID: 26040271
  90. Sun, Z.G.; Yang, Y.A.; Zhang, Z.G.; Zhu, H.L. Optimization techniques for novel c-Met kinase inhibitors. Expert Opin. Drug Discov., 2019, 14(1), 59-69. doi: 10.1080/17460441.2019.1551355 PMID: 30518273
  91. Xu, J.F.; Wang, T.T.; Yuan, Q.; Duan, Y.T.; Xu, Y.J.; Lv, P.C.; Wang, X.M.; Yang, Y.S.; Zhu, H.L. Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase. Bioorg. Med. Chem., 2019, 27(8), 1509-1516. doi: 10.1016/j.bmc.2019.02.043 PMID: 30846404
  92. London, N.; Raveh, B.; Cohen, E.; Fathi, G.; Schueler-Furman, O. Rosetta FlexPepDock web server-high resolution modeling of peptide–protein interactions. Nucleic Acids Res., 2011, 39(Web Server issue)(Suppl. 2), W249-W253. doi: 10.1093/nar/gkr431 PMID: 21622962
  93. Raveh, B.; London, N.; Zimmerman, L.; Schueler-Furman, O. Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS One, 2011, 6(4), e18934. doi: 10.1371/journal.pone.0018934 PMID: 21572516
  94. Webb, B.; Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinf., 2016, 54(1), 5-6.
  95. Lee, H.; Heo, L.; Lee, M.S.; Seok, C. GalaxyPepDock: A protein–peptide docking tool based on interaction similarity and energy optimization. Nucleic Acids Res., 2015, 43(W1), W431-W435. doi: 10.1093/nar/gkv495 PMID: 25969449
  96. Kurcinski, M.; Jamroz, M.; Blaszczyk, M.; Kolinski, A.; Kmiecik, S. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site. Nucleic Acids Res., 2015, 43(W1), W419-W424. doi: 10.1093/nar/gkv456 PMID: 25943545
  97. Wang, S.H.; Yu, J. Structure-based design for binding peptides in anti-cancer therapy. Biomaterials, 2018, 156, 1-15. doi: 10.1016/j.biomaterials.2017.11.024 PMID: 29182932
  98. Chen, X.; Zhang, W.; Yang, X.; Li, C.; Chen, H. ACP-DA: improving the prediction of anticancer peptides using data augmentation. Front. Genet., 2021, 12, 698477. doi: 10.3389/fgene.2021.698477 PMID: 34276801
  99. Boopathi, V.; Subramaniyam, S.; Malik, A.; Lee, G.; Manavalan, B.; Yang, D.C. mACPpred: a support vector machine-based meta-predictor for identification of anticancer peptides. Int. J. Mol. Sci., 2019, 20(8), 1964. doi: 10.3390/ijms20081964 PMID: 31013619
  100. Tyagi, A.; Kapoor, P.; Kumar, R.; Chaudhary, K.; Gautam, A.; Raghava, G.P.S. In silico models for designing and discovering novel anticancer peptides. Sci. Rep., 2013, 3(1), 2984. doi: 10.1038/srep02984 PMID: 24136089
  101. Chen, W.; Ding, H.; Feng, P.; Lin, H.; Chou, K.C. iACP: A sequence-based tool for identifying anticancer peptides. Oncotarget, 2016, 7(13), 16895-16909. doi: 10.18632/oncotarget.7815 PMID: 26942877
  102. Wei, L.; Zhou, C.; Chen, H.; Song, J.; Su, R. ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides. Bioinformatics, 2018, 34(23), 4007-4016. doi: 10.1093/bioinformatics/bty451 PMID: 29868903
  103. Schaduangrat, N.; Nantasenamat, C.; Prachayasittikul, V.; Shoombuatong, W. ACPred: a computational tool for the prediction and analysis of anticancer peptides. Molecules, 2019, 24(10), 1973. doi: 10.3390/molecules24101973 PMID: 31121946
  104. Ahmed, S.; Muhammod, R.; Khan, Z.H.; Adilina, S.; Sharma, A.; Shatabda, S.; Dehzangi, A. ACP-MHCNN: an accurate multi-headed deep-convolutional neural network to predict anticancer peptides. Sci. Rep., 2021, 11(1), 23676. doi: 10.1038/s41598-021-02703-3 PMID: 34880291
  105. Vijayakumar, S.; Ptv, L. ACPP: a web server for prediction and design of anti-cancer peptides. Int. J. Pept. Res. Ther., 2015, 21(1), 99-106. doi: 10.1007/s10989-014-9435-7
  106. Yi, H.C.; You, Z.H.; Zhou, X.; Cheng, L.; Li, X.; Jiang, T.H.; Chen, Z.H. ACP-DL: a deep learning long short-term memory model to predict anticancer peptides using high-efficiency feature representation. Mol. Ther. Nucleic Acids, 2019, 17, 1-9. doi: 10.1016/j.omtn.2019.04.025 PMID: 31173946
  107. Ge, R.; Feng, G.; Jing, X.; Zhang, R.; Wang, P.; Wu, Q. EnACP: an ensemble learning model for identification of anticancer peptides. Front. Genet., 2020, 11, 760. doi: 10.3389/fgene.2020.00760 PMID: 32903636
  108. Rao, B.; Zhou, C.; Zhang, G.; Su, R.; Wei, L. ACPred- Fuse: fusing multi-view information improves the prediction of anticancer peptides. Brief. Bioinform., 2020, 21(5), 1846-1855. doi: 10.1093/bib/bbz088 PMID: 31729528
  109. Xu, D.; Wu, Y.; Cheng, Z.; Yang, J.; Ding, Y. ACHP: a web server for predicting anti-cancer peptide and anti-hypertensive peptide. Int. J. Pept. Res. Ther., 2021, 27(3), 1933-1944. doi: 10.1007/s10989-021-10222-y
  110. Cao, R.; Wang, M.; Bin, Y.; Zheng, C. DLFF-ACP: prediction of ACPs based on deep learning and multi-view features fusion. PeerJ, 2021, 9, e11906. doi: 10.7717/peerj.11906 PMID: 34414035
  111. E-kobon, T.; Thongararm, P.; Roytrakul, S.; Meesuk, L.; Chumnanpuen, P. Prediction of anticancer peptides against MCF-7 breast cancer cells from the peptidomes of Achatina fulica mucus fractions. Comput. Struct. Biotechnol. J., 2016, 14, 49-57. doi: 10.1016/j.csbj.2015.11.005
  112. Xu, L.; Li, C.; An, L.; Dai, Z.; Chen, X.; You, Q.; Hu, C.; Di, B. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRASG12C. Eur. J. Med. Chem., 2020, 185, 111844. doi: 10.1016/j.ejmech.2019.111844 PMID: 31706640
  113. Henninot, A.; Collins, J.C.; Nuss, J.M. The current state of peptide drug discovery: Back to the future? J. Med. Chem., 2018, 61(4), 1382-1414. doi: 10.1021/acs.jmedchem.7b00318 PMID: 28737935
  114. Dai, Y.; Cai, X.; Shi, W.; Bi, X.; Su, X.; Pan, M.; Li, H.; Lin, H.; Huang, W.; Qian, H. Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane. Amino Acids, 2017, 49(9), 1601-1610. doi: 10.1007/s00726-017-2453-y PMID: 28664269
  115. Harris, F.; Dennison, S.R.; Singh, J.; Phoenix, D.A. On the selectivity and efficacy of defense peptides with respect to cancer cells. Med. Res. Rev., 2013, 33(1), 190-234. doi: 10.1002/med.20252 PMID: 21922503
  116. Johansson, A.C.V.; Lindahl, E. Position-resolved free energy of solvation for amino acids in lipid membranes from molecular dynamics simulations. Proteins, 2008, 70(4), 1332-1344. doi: 10.1002/prot.21629 PMID: 17876818
  117. Yamaguchi, Y.; Yamamoto, K.; Sato, Y.; Inoue, S.; Morinaga, T.; Hirano, E. Combination of aspartic acid and glutamic acid inhibits tumor cell proliferatio. Biomed. Res., 2016, 37(2), 153-159. doi: 10.2220/biomedres.37.153 PMID: 27108884
  118. Yang, B.; Zhang, C.; Li, X.; Yan, S.; Wei, W.; Wang, X.; Deng, X.; Huang, W.; Qian, H. Design, synthesis, and biological evaluation of novel peptide Gly(3)-MC62 analogues as potential antidiabetic agents. Chem. Biol. Drug Des., 2015, 86(5), 979-989. doi: 10.1111/cbdd.12564 PMID: 25845421
  119. Bhunia, D.; Mondal, P.; Das, G.; Saha, A.; Sengupta, P.; Jana, J.; Mohapatra, S.; Chatterjee, S.; Ghosh, S. Spatial position regulates power of tryptophan: discovery of a major- groove-specific nuclear-localizing, cell-penetrating tetrapeptide. J. Am. Chem. Soc., 2018, 140(5), 1697-1714. doi: 10.1021/jacs.7b10254 PMID: 29283563
  120. Hilchie, A.L.; Haney, E.F.; Pinto, D.M.; Hancock, R.E.W.; Hoskin, D.W. Enhanced killing of breast cancer cells by a d-amino acid analog of the winter flounder-derived pleurocidin NRC-03. Exp. Mol. Pathol., 2015, 99(3), 426-434. doi: 10.1016/j.yexmp.2015.08.021 PMID: 26344617
  121. Grishin, D.V.; Zhdanov, D.D.; Pokrovskaya, M.V.; Sokolov, N.N. D-amino acids in nature, agriculture and biomedicine. All Life, 2020, 13(1), 11-22. doi: 10.1080/21553769.2019.1622596
  122. Li, C.; Pazgier, M.; Li, J.; Li, C.; Liu, M.; Zou, G.; Li, Z.; Chen, J.; Tarasov, S.G.; Lu, W.Y.; Lu, W. Limitations of peptide retro-inverso isomerization in molecular mimicry. J. Biol. Chem., 2010, 285(25), 19572-19581. doi: 10.1074/jbc.M110.116814 PMID: 20382735
  123. Doti, N.; Mardirossian, M.; Sandomenico, A.; Ruvo, M.; Caporale, A. Recent applications of retro-inverso peptides. Int. J. Mol. Sci., 2021, 22(16), 8677. doi: 10.3390/ijms22168677 PMID: 34445382
  124. Chen, Y.; Mant, C.T.; Hodges, R.S. Determination of stereochemistry stability coefficients of amino acid side-chains in an amphipathic α-helix. J. Pept. Res., 2002, 59(1), 18-33. doi: 10.1046/j.1397-002x.2001.10994.x PMID: 11906604
  125. Najjar, K.; Erazo-Oliveras, A.; Brock, D.J.; Wang, T.Y.; Pellois, J.P. An l- to d-amino acid conversion in an endosomolytic analog of the cell-penetrating peptide TAT influences proteolytic stability, endocytic uptake, and endosomal escape. J. Biol. Chem., 2017, 292(3), 847-861. doi: 10.1074/jbc.M116.759837 PMID: 27923812
  126. Papo, N.; Shahar, M.; Eisenbach, L.; Shai, Y. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem., 2003, 278(23), 21018-21023. doi: 10.1074/jbc.M211204200 PMID: 12646578
  127. Papo, N.; Shai, Y. New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry, 2003, 42(31), 9346-9354. doi: 10.1021/bi027212o PMID: 12899621
  128. Abdel Monaim, S.A.H.; Jad, Y.E.; El-Faham, A.; de la Torre, B.G.; Albericio, F. Teixobactin as a scaffold for unlimited new antimicrobial peptides: SAR study. Bioorg. Med. Chem., 2018, 26(10), 2788-2796. doi: 10.1016/j.bmc.2017.09.040 PMID: 29029900
  129. Wiśniewski, K.; Galyean, R.; Tariga, H.; Alagarsamy, S.; Croston, G.; Heitzmann, J.; Kohan, A.; Wiśniewska, H.; Laporte, R.; Rivière, P.J.M.; Schteingart, C.D. New, potent, selective, and short-acting peptidic V1a receptor agonists. J. Med. Chem., 2011, 54(13), 4388-4398. doi: 10.1021/jm200278m PMID: 21688787
  130. Frey, V.; Viaud, J.; Subra, G.; Cauquil, N.; Guichou, J.F.; Casara, P.; Grassy, G.; Chavanieu, A. Structure–activity relationships of Bak derived peptides: Affinity and specificity modulations by amino acid replacement. Eur. J. Med. Chem., 2008, 43(5), 966-972. doi: 10.1016/j.ejmech.2007.06.008 PMID: 17692431
  131. Malakoutikhah, M.; Teixidó, M.; Giralt, E. Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries. J. Med. Chem., 2008, 51(16), 4881-4889. doi: 10.1021/jm800156z PMID: 18666771
  132. Huhmann, S.; Koksch, B. Fine-tuning the proteolytic stability of peptides with fluorinated amino acids. Eur. J. Org. Chem., 2018, 2018(27-28), 3667-3679. doi: 10.1002/ejoc.201800803
  133. Hicks, R.P. Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted Cα amino acids. Bioorg. Med. Chem., 2016, 24(18), 4056-4065. doi: 10.1016/j.bmc.2016.06.048 PMID: 27387357
  134. Cabrele, C.; Martinek, T.A.; Reiser, O.; Berlicki, Ł. Peptides containing β-amino acid patterns: challenges and successes in medicinal chemistry. J. Med. Chem., 2014, 57(23), 9718-9739. doi: 10.1021/jm5010896 PMID: 25207470
  135. Montero, A.; Beierle, J.M.; Olsen, C.A.; Ghadiri, M.R. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic α/β-tetrapeptide architectures. J. Am. Chem. Soc., 2009, 131(8), 3033-3041. doi: 10.1021/ja809508f PMID: 19239270
  136. Di, L. Strategic approaches to optimizing peptide ADME properties. AAPS J., 2015, 17(1), 134-143. doi: 10.1208/s12248-014-9687-3 PMID: 25366889
  137. White, C.J.; Yudin, A.K. Contemporary strategies for peptide macrocyclization. Nat. Chem., 2011, 3(7), 509-524. doi: 10.1038/nchem.1062 PMID: 21697871
  138. Schafmeister, C.E.; Po, J.; Verdine, G.L. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc., 2000, 122(24), 5891-5892. doi: 10.1021/ja000563a
  139. Carvajal, L.A.; Neriah, D.B.; Senecal, A.; Benard, L.; Thiruthuvanathan, V.; Yatsenko, T.; Narayanagari, S.R.; Wheat, J.C.; Todorova, T.I.; Mitchell, K.; Kenworthy, C.; Guerlavais, V.; Annis, D.A.; Bartholdy, B.; Will, B.; Anampa, J.D.; Mantzaris, I.; Aivado, M.; Singer, R.H.; Coleman, R.A.; Verma, A.; Steidl, U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci. Transl. Med., 2018, 10(436), eaao3003. doi: 10.1126/scitranslmed.aao3003 PMID: 29643228
  140. Fadnes, B.; Uhlin-Hansen, L.; Lindin, I.; Rekdal, Ø. Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer, 2011, 11(1), 116. doi: 10.1186/1471-2407-11-116 PMID: 21453492
  141. Sanyal, A.; Dutta, S.; Camara, A.; Chandran, A.; Koller, A.; Watson, B.G.; Sengupta, R.; Ysselstein, D.; Montenegro, P.; Cannon, J.; Rochet, J.C.; Mattoo, S. Alpha-synuclein is a target of Fic-mediated adenylylation/AMPylation: Possible implications for Parkinson’s disease. J. Mol. Biol., 2019, 431(12), 2266-2282. doi: 10.1016/j.jmb.2019.04.026 PMID: 31034889
  142. H, M.; J, F.G. Biofunctional peptides from milk proteins: mineral binding and cytomodulatory effects. Curr. Pharm. Des., 2003, 9(16), 1289-1295. doi: 10.2174/1381612033454847 PMID: 12769737
  143. Kelly, G.J.; Kia, A.F.A.; Hassan, F.; O’Grady, S.; Morgan, M.P.; Creaven, B.S.; McClean, S.; Harmey, J.H.; Devocelle, M. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells. Org. Biomol. Chem., 2016, 14(39), 9278-9286. doi: 10.1039/C6OB01815G PMID: 27722734
  144. Belén, L.H.; Rangel-Yagui, C.O.; Beltrán Lissabet, J.F.; Effer, B.; Lee-Estevez, M.; Pessoa, A.; Castillo, R.L.; Farías, J.G. From synthesis to characterization of site-selective PEGylated proteins. Front. Pharmacol., 2019, 10, 1450. doi: 10.3389/fphar.2019.01450 PMID: 31920645
  145. Milla, P.; Dosio, F.; Cattel, L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr. Drug Metab., 2012, 13(1), 105-119. doi: 10.2174/138920012798356934 PMID: 21892917
  146. Ginn, C.; Khalili, H.; Lever, R.; Brocchini, S. PEGylation and its impact on the design of new protein-based medicines. Future Med. Chem., 2014, 6(16), 1829-1846. doi: 10.4155/fmc.14.125 PMID: 25407370
  147. Shiraishi, K.; Yokoyama, M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. Sci. Technol. Adv. Mater., 2019, 20(1), 324-336. doi: 10.1080/14686996.2019.1590126 PMID: 31068982
  148. Narwal, V.; Deswal, R.; Batra, B.; Kalra, V.; Hooda, R.; Sharma, M.; Rana, J.S. Cholesterol biosensors: A review. Steroids, 2019, 143, 6-17. doi: 10.1016/j.steroids.2018.12.003 PMID: 30543816
  149. Moremen, K.W.; Tiemeyer, M.; Nairn, A.V. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol., 2012, 13(7), 448-462. doi: 10.1038/nrm3383 PMID: 22722607
  150. Pocheć, E.; Lityńska, A.; Bubka, M.; Amoresano, A.; Casbarra, A. Characterization of the oligosaccharide component of α3β1 integrin from human bladder carcinoma cell line T24 and its role in adhesion and migration. Eur. J. Cell Biol., 2006, 85(1), 47-57. doi: 10.1016/j.ejcb.2005.08.010 PMID: 16373174
  151. Moradi, S.V.; Hussein, W.M.; Varamini, P.; Simerska, P.; Toth, I. Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides. Chem. Sci. (Camb.), 2016, 7(4), 2492-2500. doi: 10.1039/C5SC04392A PMID: 28660018
  152. Zhang, P.; Ma, J.; Zhang, Q.; Jian, S.; Sun, X.; Liu, B.; Nie, L.; Liu, M.; Liang, S.; Zeng, Y.; Liu, Z. Monosaccharide analogues of anticancer peptide R-Lycosin-I: Role of monosaccharide conjugation in complexation and the potential of lung cancer targeting and therapy. J. Med. Chem., 2019, 62(17), 7857-7873. doi: 10.1021/acs.jmedchem.9b00634 PMID: 31276399
  153. Huang, C.Y.; Hsu, J.T.; Chung, P.H.; Cheng, W.T.K.; Jiang, Y.N.; Ju, Y.T. Site-specific N-glycosylation of caprine lysostaphin restricts its bacteriolytic activity toward Staphylococcus aureus. Anim. Biotechnol., 2013, 24(2), 129-147. doi: 10.1080/10495398.2012.760469 PMID: 23534959
  154. Lai, X.; Tang, J.; ElSayed, M.E.H. Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery. Expert Opin. Drug Discov., 2021, 16(12), 1467-1482. doi: 10.1080/17460441.2021.1942837 PMID: 34187273
  155. Hilchie, A.L.; Sharon, A.J.; Haney, E.F.; Hoskin, D.W.; Bally, M.B.; Franco, O.L.; Corcoran, J.A.; Hancock, R.E.W. Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma. Biochim. Biophys. Acta Biomembr., 2016, 1858(12), 3195-3204. doi: 10.1016/j.bbamem.2016.09.021 PMID: 27693190
  156. Zhang, L.; Bulaj, G. Converting peptides into drug leads by lipidation. Curr. Med. Chem., 2012, 19(11), 1602-1618. doi: 10.2174/092986712799945003 PMID: 22376031
  157. Macquaire, F.; Baleux, F.; Giaccobi, E.; Neumann, J.M.; Sanson, A.; Sanson, A. Peptide secondary structure induced by a micellar phospholipidic interface: proton NMR conformational study of a lipopeptide. Biochemistry, 1992, 31(9), 2576-2582. doi: 10.1021/bi00124a018 PMID: 1547240
  158. Aicart-Ramos, C.; Valero, R.A.; Rodriguez-Crespo, I. Protein palmitoylation and subcellular trafficking. Biochim. Biophys. Acta Biomembr., 2011, 1808(12), 2981-2994. doi: 10.1016/j.bbamem.2011.07.009 PMID: 21819967
  159. Jiang, H.; Zhang, X.; Chen, X.; Aramsangtienchai, P.; Tong, Z.; Lin, H. Protein lipidation: occurrence, mechanisms, biological functions, and enabling technologies. Chem. Rev., 2018, 118(3), 919-988. doi: 10.1021/acs.chemrev.6b00750 PMID: 29292991
  160. Roxin, Á.; Zheng, G. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides. Future Med. Chem., 2012, 4(12), 1601-1618. doi: 10.4155/fmc.12.75 PMID: 22917248
  161. Chatterjee, J.; Rechenmacher, F.; Kessler, H. N-methylation of peptides and proteins: an important element for modulating biological functions. Angew. Chem. Int. Ed., 2013, 52(1), 254-269. doi: 10.1002/anie.201205674 PMID: 23161799
  162. Ványolós, A.; Dékány, M.; Kovács, B.; Krámos, B.; Bérdi, P.; Zupkó, I.; Hohmann, J.; Béni, Z. Gymnopeptides A and B, cyclic octadecapeptides from the mushroom gymnopus fusipes. Org. Lett., 2016, 18(11), 2688-2691. doi: 10.1021/acs.orglett.6b01158 PMID: 27194202
  163. Pan, Z.; Wu, C.; Wang, W.; Cheng, Z.; Yao, G.; Liu, K.; Li, H.; Fang, L.; Su, W. Total synthesis and stereochemical assignment of gymnopeptides A and B. Org. Lett., 2017, 19(17), 4420-4423. doi: 10.1021/acs.orglett.7b01742 PMID: 28799768
  164. Li, J.; Koh, J.J.; Liu, S.; Lakshminarayanan, R.; Verma, C.S.; Beuerman, R.W. Membrane active antimicrobial peptides: translating mechanistic insights to design. Front. Neurosci., 2017, 11, 73. doi: 10.3389/fnins.2017.00073 PMID: 28261050
  165. Klimpel, A.; Lützenburg, T.; Neundorf, I. Recent advances of anti-cancer therapies including the use of cell-penetrating peptides. Curr. Opin. Pharmacol., 2019, 47, 8-13. doi: 10.1016/j.coph.2019.01.003 PMID: 30771730
  166. El-Sayed, A.; Futaki, S.; Harashima, H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J., 2009, 11(1), 13-22. doi: 10.1208/s12248-008-9071-2 PMID: 19125334
  167. Regberg, J.; Srimanee, A.; Langel, Ü. Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals (Basel), 2012, 5(9), 991-1007. doi: 10.3390/ph5090991 PMID: 24280701
  168. Dokka, S.; Toledo-Velasquez, D.; Shi, X.; Wang, L.; Rojanasakul, Y. Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm. Res., 1997, 14(12), 1759-1764. doi: 10.1023/A:1012188014919 PMID: 9453065
  169. Nakayama, F.; Yasuda, T.; Umeda, S.; Asada, M.; Imamura, T.; Meineke, V.; Akashi, M. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: involvement of internalization in the in vivo role of exogenous FGF12. J. Biol. Chem., 2011, 286(29), 25823-25834. doi: 10.1074/jbc.M110.198267 PMID: 21518765
  170. Tian, H.; Lin, L.; Chen, J.; Chen, X.; Park, T.G.; Maruyama, A. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. J. Control. Release, 2011, 155(1), 47-53. doi: 10.1016/j.jconrel.2011.01.025 PMID: 21281679
  171. Tang, B.; Zaro, J.L.; Shen, Y.; Chen, Q.; Yu, Y.; Sun, P.; Wang, Y.; Shen, W.C.; Tu, J.; Sun, C. Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting. J. Control. Release, 2018, 279, 147-156. doi: 10.1016/j.jconrel.2018.04.016 PMID: 29653223
  172. Hogervorst, T.P.; Li, R.J.E.; Marino, L.; Bruijns, S.C.M.; Meeuwenoord, N.J.; Filippov, D.V.; Overkleeft, H.S.; van der Marel, G.A.; van Vliet, S.J.; van Kooyk, Y.; Codée, J.D.C. C-mannosyl lysine for solid phase assembly of mannosylated peptide conjugate cancer vaccines. ACS Chem. Biol., 2020, 15(3), 728-739. doi: 10.1021/acschembio.9b00987 PMID: 32045202
  173. Habault, J.; Kaci, A.; Pasquereau-Kotula, E.; Fraser, C.; Chomienne, C.; Dombret, H.; Braun, T.; Pla, M.; Poyet, J.L. Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53. OncoImmunology, 2020, 9(1), 1728871. doi: 10.1080/2162402X.2020.1728871 PMID: 32158621
  174. Noguchi, M.; Arai, G.; Matsumoto, K.; Naito, S.; Moriya, F.; Suekane, S.; Komatsu, N.; Matsueda, S.; Sasada, T.; Yamada, A.; Kakuma, T.; Itoh, K. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunol. Immunother., 2015, 64(4), 493-505. doi: 10.1007/s00262-015-1660-1 PMID: 25662406
  175. Noguchi, M.; Arai, G.; Egawa, S.; Ohyama, C.; Naito, S.; Matsumoto, K.; Uemura, H.; Nakagawa, M.; Nasu, Y.; Eto, M.; Suekane, S.; Sasada, T.; Shichijo, S.; Yamada, A.; Kakuma, T.; Itoh, K. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunol. Immunother., 2020, 69(5), 847-857. doi: 10.1007/s00262-020-02498-8 PMID: 32025848
  176. Murahashi, M.; Hijikata, Y.; Yamada, K.; Tanaka, Y.; Kishimoto, J.; Inoue, H.; Marumoto, T.; Takahashi, A.; Okazaki, T.; Takeda, K.; Hirakawa, M.; Fujii, H.; Okano, S.; Morita, M.; Baba, E.; Mizumoto, K.; Maehara, Y.; Tanaka, M.; Akashi, K.; Nakanishi, Y.; Yoshida, K.; Tsunoda, T.; Tamura, K.; Nakamura, Y.; Tani, K. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin. Immunol., 2016, 166-167, 48-58. doi: 10.1016/j.clim.2016.03.015 PMID: 27072896
  177. Nishida, S.; Morimoto, S.; Oji, Y.; Morita, S.; Shirakata, T.; Enomoto, T.; Tsuboi, A.; Ueda, Y.; Yoshino, K.; Shouq, A.; Kanegae, M.; Ohno, S.; Fujiki, F.; Nakajima, H.; Nakae, Y.; Nakata, J.; Hosen, N.; Kumanogoh, A.; Oka, Y.; Kimura, T.; Sugiyama, H. Cellular and humoral immune responses induced by an HLA class I-restricted peptide cancer vaccine targeting WT1 are associated with favorable clinical outcomes in advanced ovarian cancer. J. Immunother., 2022, 45(1), 56-66. doi: 10.1097/CJI.0000000000000405 PMID: 34874330
  178. Zhang, Y.; He, P.; Zhang, P.; Yi, X.; Xiao, C.; Chen, X. Polypeptides–drug conjugates for anticancer therapy. Adv. Healthc. Mater., 2021, 10(11), 2001974. doi: 10.1002/adhm.202001974 PMID: 33929786
  179. Fan, R.; Tong, A.; Li, X.; Gao, X.; Mei, L.; Zhou, L.; Zhang, X.; You, C.; Guo, G. Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. Int. J. Nanomed., 2015, 10, 7291-7305. PMID: 26664119
  180. Hassanvand Jamadi, R.; Asadi, A.; Yaghoubi, H.; Goudarzi, F. Investigation into the anticancer activity and apoptosis induction of Brevinin-2R and Brevinin-2R-conjugated PLA-PEG-PLA nanoparticles and strong cell cycle arrest in AGS, HepG2 and KYSE-30 cell lines. Int. J. Pept. Res. Ther., 2019, 25(3), 1225-1239. doi: 10.1007/s10989-018-9772-z
  181. Li, G.; Lei, Q.; Wang, F.; Deng, D.; Wang, S.; Tian, L.; Shen, W.; Cheng, Y.; Liu, Z.; Wu, S. Fluorinated polymer mediated transmucosal peptide delivery for intravesical instillation therapy of bladder cancer. Small, 2019, 15(25), 1900936. doi: 10.1002/smll.201900936 PMID: 31074941
  182. Merrifield, R.B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide J. Am. Chem. Soc., 1963, 85(14), 2149-2154. doi: 10.1021/ja00897a025
  183. Lau, J.L.; Dunn, M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg. Med. Chem., 2018, 26(10), 2700-2707. doi: 10.1016/j.bmc.2017.06.052 PMID: 28720325
  184. Komin, A.; Russell, L.M.; Hristova, K.A.; Searson, P.C. Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges. Adv. Drug Deliv. Rev., 2017, 110-111, 52-64. doi: 10.1016/j.addr.2016.06.002 PMID: 27313077
  185. Conibear, A.C.; Watson, E.E.; Payne, R.J.; Becker, C.F.W. Native chemical ligation in protein synthesis and semi-synthesis. Chem. Soc. Rev., 2018, 47(24), 9046-9068. doi: 10.1039/C8CS00573G PMID: 30418441

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers